文献速递肝病

随机临床试验:恩利卡生对比安慰剂显著降低非酒精性脂肪性肝病受试者的丙氨酸氨基转移酶及半胱天冬酶3/7活化

Randomised clinical trial: emricasan versus placebo significantly decreases ALT and caspase 3/7 activation in subjects with non-alcoholic fatty liver disease.
PubMed 文献 · Aliment Pharmacol Ther · 2018-11-14

这项双盲、安慰剂对照、诊所实践研究将38例非酒精性脂肪性肝病且筛选期ALT≥1.5倍正常值上限的受试者随机分至恩利卡生25mg每日两次组或安慰剂组,各19例。第28天恩利卡生组ALT较安慰剂组显著下降(第7天P<0.0001,第28天P=0.02),cCK18、flCK18及半胱天冬酶3/7亦显著降低,治疗总体安全且耐受良好。

要点

  • 恩利卡生25mg每日两次治疗28天可显著降低NAFLD患者升高的ALT。
  • 恩利卡生组cCK18(第7天)、flCK18(第7、28天)、半胱天冬酶3/7(第7天)较安慰剂显著下降。
  • 恩利卡生治疗总体安全且耐受良好。

核心结论

  • 恩利卡生在非酒精性脂肪性肝病且转氨酶升高的受试者中治疗28天后降低了ALT和生物标志物,结果支持在非酒精性脂肪性肝病患者中进一步开发恩利卡生。

研究设计与样本

  • 双盲、安慰剂对照、诊所实践研究,评估恩利卡生在非酒精性脂肪性肝病且筛选期ALT≥1.5倍正常值上限受试者中的疗效、安全性和耐受性。
  • 38例受试者随机分组,恩利卡生组19例、安慰剂组19例,分别接受恩利卡生25mg每日两次或匹配安慰剂。
  • 排除肝硬化及因其他原因导致转氨酶升高的受试者。
  • 主要终点为第28天恩利卡生组相较安慰剂组的ALT变化。

主要发现

  • 基线疾病因素总体均衡,但恩利卡生组中位ALT值较低。
  • 随机至安慰剂组的3例受试者在第28天前退出。
  • ALT在恩利卡生治疗组较安慰剂组于第7天(P<0.0001)和第28天(P=0.02)显著下降。
  • cCK18(第7天)、flCK18(第7天和第28天)及半胱天冬酶3/7(第7天)在恩利卡生治疗组较安慰剂组亦显著下降。
  • 恩利卡生治疗总体安全且耐受良好。

临床怎么用

  • 原文结论为恩利卡生降低了非酒精性脂肪性肝病且转氨酶升高受试者的ALT和生物标志物,并支持在非酒精性脂肪性肝病患者中进一步开发恩利卡生。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Lipotoxicity leading to excessive caspase-mediated apoptosis and inflammation is believed to drive liver damage in NAFLD. Emricasan is a pan-caspase inhibitor that decreased serum ALT and apoptotic and inflammatory markers in subjects with chronic hepatitis. AIMS: To assess whether 28 days of emricasan would reduce elevated levels of serum ALT, AST, cleaved cytokeratin-18, full-length cytokeratin-18, and caspase 3/7 in subjects with NAFLD and raised aminotransferases. METHODS: Double-blind, placebo-controlled, office-practice study assessed the efficacy, safety, and tolerability of emricasan in subjects with NAFLD and ALT levels ≥1.5 x ULN during screening. Subjects were randomised to emricasan 25 mg twice daily or matching placebo. Subjects with cirrhosis and other causes for raised aminotransferases were excluded. The primary endpoint was the change in ALT at day 28 in the emricasan group vs placebo. RESULTS: 38 subjects were randomised, 19 each to emricasan or placebo. Baseline disease factors were well balanced except for lower median ALT values in emricasan subjects. Three subjects randomised to placebo discontinued prior to day 28. ALT values decreased significantly in emricasan-treated subjects vs placebo at days 7 (P < 0.0001) and 28 (P = 0.02). cCK18 (day 7), flCK18 (days 7 and 28), and caspase 3/7 (day 7) were also significantly decreased in emricasan-treated subjects vs placebo. Emricasan treatment was generally safe and well tolerated. CONCLUSIONS: Emricasan decreased ALT and biomarkers in subjects with NAFLD and raised aminotransferases after 28 days. These results support the further development of emricasan in patients with NAFLD. TRIAL REGISTRATION: ClinicalTrials.gov, Identifier: NCT02077374.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Shiffman M, Freilich B, Vuppalanchi R, et al. Randomised clinical trial: emricasan versus placebo significantly decreases ALT and caspase 3/7 activation in subjects with non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2018. PMID: 30430605. doi:10.1111/apt.15030

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。